JP6166736B2 - （６ｓ）−５−メチルテトラヒドロ葉酸塩の結晶形及びそれを製造する方法 - Google Patents

（６ｓ）−５−メチルテトラヒドロ葉酸塩の結晶形及びそれを製造する方法 Download PDF

Info

Publication number
JP6166736B2
JP6166736B2 JP2014552484A JP2014552484A JP6166736B2 JP 6166736 B2 JP6166736 B2 JP 6166736B2 JP 2014552484 A JP2014552484 A JP 2014552484A JP 2014552484 A JP2014552484 A JP 2014552484A JP 6166736 B2 JP6166736 B2 JP 6166736B2
Authority
JP
Japan
Prior art keywords
methyltetrahydrofolate
crystalline form
calcium salt
type
ray diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014552484A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015506941A5 (enrdf_load_stackoverflow
JP2015506941A (ja
Inventor
王哲清
成永之
恒 黄
恒 黄
李慧珍
Original Assignee
連雲港金康和信薬業有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201210019038.4A external-priority patent/CN102584826B/zh
Priority claimed from CN201210018941.9A external-priority patent/CN102775407B/zh
Priority claimed from CN201210125133.2A external-priority patent/CN102702200B/zh
Application filed by 連雲港金康和信薬業有限公司 filed Critical 連雲港金康和信薬業有限公司
Publication of JP2015506941A publication Critical patent/JP2015506941A/ja
Publication of JP2015506941A5 publication Critical patent/JP2015506941A5/ja
Application granted granted Critical
Publication of JP6166736B2 publication Critical patent/JP6166736B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B30/00—Production of single crystals or homogeneous polycrystalline material with defined structure characterised by the action of electric or magnetic fields, wave energy or other specific physical conditions
    • C30B30/06—Production of single crystals or homogeneous polycrystalline material with defined structure characterised by the action of electric or magnetic fields, wave energy or other specific physical conditions using mechanical vibrations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/14—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Mechanical Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014552484A 2012-01-20 2012-12-17 （６ｓ）−５−メチルテトラヒドロ葉酸塩の結晶形及びそれを製造する方法 Active JP6166736B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201210019038.4A CN102584826B (zh) 2012-01-20 2012-01-20 (6s)-5-甲基四氢叶酸盐晶型及其制备方法
CN201210018941.9A CN102775407B (zh) 2012-01-20 2012-01-20 稳定的无定型5-甲基四氢叶酸盐及其制备方法
CN201210019038.4 2012-01-20
CN201210018941.9 2012-01-20
CN201210125133.2A CN102702200B (zh) 2012-04-25 2012-04-25 (6rs)-5-甲基四氢叶酸钙盐晶型及其制备方法
CN201210125133.2 2012-04-25
PCT/CN2012/086794 WO2013107236A1 (zh) 2012-01-20 2012-12-17 （6s）-5-甲基四氢叶酸盐晶型及其制备方法

Publications (3)

Publication Number Publication Date
JP2015506941A JP2015506941A (ja) 2015-03-05
JP2015506941A5 JP2015506941A5 (enrdf_load_stackoverflow) 2015-11-26
JP6166736B2 true JP6166736B2 (ja) 2017-07-19

Family

ID=48798580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014552484A Active JP6166736B2 (ja) 2012-01-20 2012-12-17 （６ｓ）−５−メチルテトラヒドロ葉酸塩の結晶形及びそれを製造する方法

Country Status (11)

Country Link
US (1) US9150982B2 (enrdf_load_stackoverflow)
EP (1) EP2805952B1 (enrdf_load_stackoverflow)
JP (1) JP6166736B2 (enrdf_load_stackoverflow)
KR (1) KR101694710B1 (enrdf_load_stackoverflow)
BR (1) BR112014017939A2 (enrdf_load_stackoverflow)
CA (1) CA2861891C (enrdf_load_stackoverflow)
ES (1) ES2715599T3 (enrdf_load_stackoverflow)
HR (1) HRP20190317T1 (enrdf_load_stackoverflow)
IN (1) IN2014DN06942A (enrdf_load_stackoverflow)
PL (1) PL2805952T3 (enrdf_load_stackoverflow)
WO (1) WO2013107236A1 (enrdf_load_stackoverflow)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015193778A1 (en) 2014-06-16 2015-12-23 Mylan Laboratories Ltd. Crystalline form of levomefolate calcium
KR20170047394A (ko) 2014-09-04 2017-05-04 리안윤강 진강 해신 파머수티컬 코. 엘티디. (6s)-5-메틸테트라히드로폴산 또는 그 염의 조성물 및 그 제조와 용도
CA3058287A1 (en) 2017-03-31 2018-10-04 Merck Patent Gmbh Crystalline sodium salt of 5-methyl-(6s)-tetrahydrofolic acid
US11377448B2 (en) 2017-03-31 2022-07-05 Merck Patent Gmbh Crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid
JP7422124B2 (ja) * 2018-07-06 2024-01-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ５－メチル－（６ｓ）－テトラヒドロ葉酸及びｌ－バリンエチルエステルの結晶性塩
JP7681000B2 (ja) * 2019-08-06 2025-05-21 リェンユンガン ジンカン ヘキシン ファーマシューティカル カンパニー リミテッド アフリカ豚熱を治療するための薬物組成物及びその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223500A (en) 1977-02-22 1993-06-29 Bioresearch S.P.A. Stable pharmaceutical composition of alkaline or alkaline earth 5-methyl tetrahydrofolate
US5471001A (en) * 1994-12-15 1995-11-28 E. I. Du Pont De Nemours And Company Crystallization of adipic acid
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
DE10137017A1 (de) * 2001-07-30 2003-02-20 Basf Ag Kristallisationsverfahren zur Einstellung kleiner Partikel
US20090298884A1 (en) * 2005-05-06 2009-12-03 Glenmark Generics Ltd. Esomeprazole Strontium Salt, Process For Its Preparation and Pharmaceutical Compositions Containing Same
CN100336814C (zh) * 2005-11-23 2007-09-12 天津大学 溶剂超声协同作用制备球状结晶核黄素方法
KR100878140B1 (ko) * 2007-01-29 2009-01-12 한미약품 주식회사 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
CH698729B1 (de) 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
CN102775407B (zh) * 2012-01-20 2015-08-05 连云港金康医药科技有限公司 稳定的无定型5-甲基四氢叶酸盐及其制备方法
CN102702200B (zh) * 2012-04-25 2014-11-12 连云港金康和信药业有限公司 (6rs)-5-甲基四氢叶酸钙盐晶型及其制备方法
CN102584826B (zh) * 2012-01-20 2015-04-29 连云港金康医药科技有限公司 (6s)-5-甲基四氢叶酸盐晶型及其制备方法

Also Published As

Publication number Publication date
US20150018357A1 (en) 2015-01-15
IN2014DN06942A (enrdf_load_stackoverflow) 2015-04-10
EP2805952B1 (en) 2019-02-06
EP2805952A4 (en) 2015-07-01
HRP20190317T1 (hr) 2019-05-03
BR112014017939A2 (pt) 2021-05-25
US9150982B2 (en) 2015-10-06
ES2715599T3 (es) 2019-06-05
CA2861891C (en) 2018-06-19
KR20140113740A (ko) 2014-09-24
EP2805952A1 (en) 2014-11-26
BR112014017939A8 (pt) 2017-07-11
PL2805952T3 (pl) 2019-05-31
JP2015506941A (ja) 2015-03-05
CA2861891A1 (en) 2013-07-25
KR101694710B1 (ko) 2017-01-10
WO2013107236A1 (zh) 2013-07-25

Similar Documents

Publication Publication Date Title
JP6166736B2 (ja) （６ｓ）−５−メチルテトラヒドロ葉酸塩の結晶形及びそれを製造する方法
CN104744462B (zh) 吡咯并喹啉醌的钠盐结晶、其制法、功能性食品和医药
CN103119044B (zh) 吡咯并喹啉醌的钙盐
JP2016504277A (ja) ピロロキノリンキノン二ナトリウム塩の結晶
AU2015311370A1 (en) Composition of (6S)-5-methyl tetrahydrofolic acid or salt thereof as well as preparation therefor and application thereof
WO2012070649A1 (ja) 溶解性の高いピロロキノリンキノン塩及びその製造方法
US20060286166A1 (en) Tadalafil having a large particle size and a process for preparation thereof
CN104557937B (zh) (6s)‑5‑甲基四氢叶酸盐晶型及其制备方法
JP2014524931A (ja) ４−ｔｅｒｔ−ブチル−Ｎ−［４−クロロ−２−（１−オキシ−ピリジン−４−カルボニル）−フェニル］−ベンゼンスルホンアミドのナトリウム塩の結晶形
JP2025061823A (ja) 葉酸塩
JP2014521645A (ja) ４−ｔｅｒｔ−ブチル−Ｎ−［４−クロロ−２−（１−オキシ−ピリジン−４−カルボニル）−フェニル］−ベンゼンスルホンアミドのナトリウム塩の多形
JP5636671B2 (ja) ピロロキノリンキノンＬｉ塩の製造方法
EP2946781B1 (en) Crystalline levofolinic acid and process for its preparation
CN102775407B (zh) 稳定的无定型5-甲基四氢叶酸盐及其制备方法
CN104530051B (zh) 稳定的(6r,s)-5-甲基四氢叶酸晶型及其制备方法
JP2020512383A (ja) ５−メチル−（６ｓ）−テトラヒドロ葉酸の結晶性ナトリウム塩
JPWO2020089443A5 (ja) 葉酸塩の塩類

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151007

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170302

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170327

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170606

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170623

R150 Certificate of patent or registration of utility model

Ref document number: 6166736

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250